The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESH CLL 2022 | Efficacy of ibrutinib in the treatment of CLL patients with del(17p) and TP53 mutation
In this video, John Allan, MD, Weill Cornell Medicine, New York, NY, discusses the promising data obtained from the use of ibrutinib and other Bruton’s tyrosine kinase (BTK) inhibitors in the treatment of chronic lymphocytic leukemia (CLL) patients with del(17p) and TP53 mutation. Dr Allan first highlights the poor prognosis associated with these patients, and then discusses the encouraging outcomes that have been observed in patients treated with ibrutinib and other FDA-approved BTK inhibitors. To conclude, Dr Allan mentions how these novel therapeutic agents are very promising for the future of CLL and are moving the treatment of high-risk patients in the right direction. This interview took place during the 2nd ESH Translational Research Conference on Chronic Lymphocytic Leukemia (ESH CLL), 2022.
Disclosures
(Consultancy: Abbvie, AstraZenenca, BeiGene, Genentech, Janssen, Pharmacyclics) Research Genentech, Janssen
